OAM
IDXG

Oxford Asset Management’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Oxford Asset Management’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,008
Closed -$24K – 2167
2018
Q4 		$24K Buy
+3,008
New +$36.1K ﹤0.01% 1734

Other funds holding IDXG

PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

Oxford Asset Management's IDXG Position: Q1 2019 in Review

Oxford Asset Management sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2019, closing a stake of 3,008 shares — an estimated $24K sold.

Oxford Asset Management first reported a position in IDXG in Q4 2018 and held it in 1 quarter. The position peaked at $24K in Q4 2018. 20 funds tracked by Wall St. Rank hold IDXG as of Q1 2019.

  • Oxford Asset Management reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Oxford Asset Management sold 3,008 Interpace Biosciences, Inc. Common Stock shares in Q1 2019, an estimated $24K.
  • Oxford Asset Management first reported a position in Interpace Biosciences, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Oxford Asset Management's Interpace Biosciences, Inc. Common Stock position peaked at $24K in Q4 2018.
  • 20 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.